STING Agonist
STING agonists are a class of innate immune–activating therapeutic agents that stimulate the Stimulator of Interferon Genes (STING) pathway, a key cytosolic DNA-sensing mechanism in the innate immune system. STING functions as a central receptor that detects aberrant cytosolic DNA derived from pathogens or tumor cells, triggering downstream signaling that induces type I interferons and pro-inflammatory cytokines. By activating this pathway, STING agonists enhance innate and adaptive immune responses, promote anti-tumor immunity, and are being actively explored in cancer immunotherapy, infectious disease treatment, and vaccine adjuvant development.
Explore By Category
Cytosolic DNA-Sensing STING Pathway Activation
Cytosolic DNA-sensing STING pathway activation refers to the immune signaling cascade initiated when STING detects abnormal DNA in the cytoplasm, leading to the production of type I interferons and inflammatory cytokines that coordinate innate and adaptive immune responses.
STING-Mediated Anti-Tumor Immunity Enhancement
STING-mediated anti-tumor immunity enhancement describes the therapeutic activation of the STING pathway to stimulate immune cell infiltration and cytokine production, thereby strengthening immune recognition and destruction of tumor cells in cancer immunotherapy.
